With $110M and UMass Medical School technology, therapeutics

A new therapeutics company is getting started by three UMass Medical School researchers with $110 million in funding and the use of technology licensed from the Worcester school.
At the heart of the new Boston company, Atalanta Therapeutics, is a proprietary technology licensed by UMass Medical School, which is a part-founder along with three of its researchers: Anastasia Khvorova, Craig Mello and Neil Aronin. They're using a proprietary technology licensed by the medical school called branched siRNA, an advancement in gene capabilities, that aims to treat neurodegenerative diseases.
UMass Medical School's co-founders are among three of its top researchers, Atalanta said.

Related Keywords

Boston , Massachusetts , United States , Worcester , Cambridge , Cambridgeshire , United Kingdom , Switzerland , Swiss , Craig Mello , Anastasia Khvorova , Neil Aronin , Genentech , Umass Medical School , Medical School , Atalanta Therapeutics , Nobel Prize , F Prime Capital , போஸ்டன் , மாசசூசெட்ஸ் , ஒன்றுபட்டது மாநிலங்களில் , வர்ஸெஸ்டர் , கேம்பிரிட்ஜ் , கேம்பிரிட்ஜ்ஷைர் , ஒன்றுபட்டது கிஂக்டம் , சுவிட்சர்லாந்து , சுவிஸ் , கிரேக் மெல்லோ , ஜெநிஂடெக் , உமஸ்ஸ் மருத்துவ பள்ளி , மருத்துவ பள்ளி , அடலெஂட சிகிச்சை , நோபல் ப்ரைஸ் , எஃப் ப்ரைம் மூலதனம் ,